Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...

Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...

Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Werewolf Therapeutics, Inc. (HOWL) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, HOWL's 50-day simple moving average ...

Detailed price information for Werewolf Therapeutics Inc (HOWL-Q) from The Globe and Mail including charting and trades.

Wall Street expects a year-over-year decline in earnings on higher revenues when Werewolf Therapeutics, Inc. (HOWL) reports results for the quarter ended March 2025. While this widely-known consensus ...

Director Luke Evnin reported selling shares of Werewolf Therapeutics Inc (NASDAQ:HOWL) between December 2nd and December 4th, 2025. The sales, executed under a prearranged 10b5-1 trading plan, totaled ...

Director Luke Evnin of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) recently sold a total of 199,356 shares of common stock in three separate transactions, netting approximately $251,348. The sale comes ...

Detailed price information for Werewolf Therapeutics Inc (HOWL-Q) from The Globe and Mail including charting and trades.

A 10% owner of Werewolf Therapeutics Inc (NASDAQ:HOWL), including MPM Asset Management LLC and related entities, reported selling 160,103 shares of common stock over three days, according to a Form 4 ...